Literature DB >> 31277825

A New Method to Determine the Optimal Willingness to Pay in Cost-Effectiveness Analysis.

Charles E Phelps1.   

Abstract

OBJECTIVE: To provide a new approach to estimate optimal willingness to pay (WTP) for health technology assessment (HTA). STUDY
DESIGN: This analysis specified utility as a function of income and calibrated it using estimates of relative risk aversion, from which the optimal WTP (K) can be determined using Garber and Phelps' results (1997).
METHODS: This analysis used the highly flexible Weibull utility function, calibrated with estimates of relative risk aversion (r*) derived from multiple data sources. The analysis centered on r* = 1 and conducted sensitivity analysis on r* and key Weibull parameters. For a range of income (M), graphs demonstrated how K/M and K vary with M. Results were compared with estimates of K and K/M from alternative models. Extrapolation from a representative individual to population-wide health plans was discussed.
RESULTS: Using r* = 1 and central values of other key parameters, K/M (at average income for developed nations) was approximately 2× annual income. Both K and K/M rose with income. Sensitivity analysis showed that results depend moderately on the chosen value of r* and specific Weibull utility function parameters. At average income, the optimal K/M ratio (2×) was modestly lower than many standard recommendations (typically 3× average income) and substantially lower than estimates using value-of-statistical-life approaches.
CONCLUSIONS: The new model, although not yet perfected, provides a different way to identify the WTP cutoff for HTA. Extrapolation to more than twice the calibration income ($50 000) is advised against. Analysis of other approaches to estimate the optimal K reveal potential upward biases.
Copyright © 2019 ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.

Keywords:  cost-effectiveness analysis; cost-effectiveness cutoff; health technology assessment; willingness to pay

Year:  2019        PMID: 31277825     DOI: 10.1016/j.jval.2019.03.003

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  5 in total

1.  Health technology assessment with risk aversion in health.

Authors:  Darius N Lakdawalla; Charles E Phelps
Journal:  J Health Econ       Date:  2020-06-06       Impact factor: 3.883

2.  Affordability and Value in Decision Rules for Cost-Effectiveness: A Survey of Health Economists.

Authors:  Alyssa Bilinski; Evan MacKay; Joshua A Salomon; Ankur Pandya
Journal:  Value Health       Date:  2022-02-24       Impact factor: 5.101

3.  Value-based drug pricing in the Biden era: Opportunities and prospects.

Authors:  Peter J Neumann; Daniel A Ollendorf; Joshua T Cohen
Journal:  Health Serv Res       Date:  2021-06-03       Impact factor: 3.734

4.  The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19.

Authors:  Melanie D Whittington; Steven D Pearson; David M Rind; Jonathan D Campbell
Journal:  Value Health       Date:  2022-02-19       Impact factor: 5.101

5.  A guide to extending and implementing generalized risk-adjusted cost-effectiveness (GRACE).

Authors:  Darius N Lakdawalla; Charles E Phelps
Journal:  Eur J Health Econ       Date:  2021-09-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.